Editas Medicine, Inc. (EDIT)
2.17
+0.03
(+1.40%)
USD |
NASDAQ |
Nov 13, 16:00
2.165
0.00 (0.00%)
After-Hours: 19:59
Editas Medicine Shareholders Equity (Quarterly) : 84.52M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 84.52M |
| June 30, 2026 | 105.28M |
| March 31, 2026 | 4.408M |
| December 31, 2025 | 27.29M |
| September 30, 2025 | 13.45M |
| June 30, 2025 | 19.19M |
| March 31, 2025 | 62.42M |
| December 31, 2024 | 134.27M |
| September 30, 2024 | 175.63M |
| June 30, 2024 | 232.01M |
| March 31, 2024 | 294.40M |
| December 31, 2023 | 349.10M |
| September 30, 2023 | 360.46M |
| June 30, 2023 | 399.92M |
| March 31, 2023 | 317.47M |
| December 31, 2022 | 360.68M |
| September 30, 2022 | 414.74M |
| June 30, 2022 | 465.41M |
| March 31, 2022 | 512.76M |
| December 31, 2021 | 553.64M |
| September 30, 2021 | 586.79M |
| June 30, 2021 | 613.36M |
| Date | Value |
|---|---|
| March 31, 2021 | 638.00M |
| December 31, 2020 | 393.59M |
| September 30, 2020 | 441.15M |
| June 30, 2020 | 426.77M |
| March 31, 2020 | 234.57M |
| December 31, 2019 | 262.44M |
| September 30, 2019 | 209.99M |
| June 30, 2019 | 193.06M |
| March 31, 2019 | 217.16M |
| December 31, 2018 | 236.16M |
| September 30, 2018 | 224.45M |
| June 30, 2018 | 231.33M |
| March 31, 2018 | 247.52M |
| December 31, 2017 | 208.08M |
| September 30, 2017 | 177.79M |
| June 30, 2017 | 185.00M |
| March 31, 2017 | 206.46M |
| December 31, 2016 | 134.61M |
| September 30, 2016 | 170.18M |
| June 30, 2016 | 187.33M |
| March 31, 2016 | 201.36M |
| December 31, 2015 | 116.80M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 3.604B |
| Vertex Pharmaceuticals, Inc. | 20.91B |
| Recursion Pharmaceuticals, Inc. | 905.81M |
| Halozyme Therapeutics, Inc. | -55.24M |
| Novavax, Inc. | -216.86M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 219.41M |
| Total Liabilities (Quarterly) | 134.89M |
| Debt to Equity Ratio | 0.8372 |
| Current Ratio | 2.822 |
| Net Debt Paydown Yield | 0.36% |